CLRB · Company research
Cellectar Biosciences INC NEW (CLRB): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
15records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Cancer treatment responses lasted a median 16 months in Cellectar's study - Stock Titan | Cancer treatment responses lasted a median 16 months in Cellectar's study Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| Cellectar Biosciences Share Price - CLRB, RNS News, Articles, Quotes, & Charts (NASDAQ:CLRB) - Proactive financial news | Cellectar Biosciences Share Price - CLRB, RNS News, Articles, Quotes, & Charts (NASDAQ:CLRB) Proactive financial news | View source ↗ | Proactive financial news | Oct 13, 2026 | neutral | 0 | 0.6 |
| Cellectar Biosciences (CLRB) Slips 4.30% as Shares Test Lower End of Recent Range - ETF Creation Redemption - siam.in | Cellectar Biosciences (CLRB) Slips 4.30% as Shares Test Lower End of Recent Range - ETF Creation Redemption siam.in | View source ↗ | siam.in | Oct 4, 2026 | neutral | 0 | 0.6 |
| A cancer drug produced responses in 87.5% of patients resistant to a prior cancer treatment - Stock Titan | A cancer drug produced responses in 87.5% of patients resistant to a prior cancer treatment Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy - Slideshow (NASDAQ:CLRB) 2026-08-18 - Seeking Alpha | Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy - Slideshow (NASDAQ:CLRB) 2026-08-18 Seeking Alpha | View source ↗ | Seeking Alpha | Aug 18, 2026 | neutral | 0 | 0.6 |
| Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk - Yahoo Finance | Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk Yahoo Finance | View source ↗ | Yahoo Finance | Jul 11, 2026 | neutral | 0 | 0.6 |
| CLRB Forecast — Price Target — Prediction for 2027 - TradingView | CLRB Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| CLRB - Finviz | CLRB Finviz | View source ↗ | Finviz | May 26, 2026 | neutral | 0 | 0.6 |
| Should I buy Cellectar Biosciences (CLRB) - Zacks Investment Research | Should I buy Cellectar Biosciences (CLRB) Zacks Investment Research | View source ↗ | Zacks Investment Research | May 7, 2026 | neutral | 0 | 0.6 |
| Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance | Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | May 7, 2026 | neutral | 0 | 0.6 |
| CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data - Stocktwits | CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data Stocktwits | View source ↗ | Stocktwits | May 5, 2026 | neutral | 0 | 0.6 |
| CLRB Stock Jumps As New Breast Cancer Trial Begins - www.timothysykes.com | CLRB Stock Jumps As New Breast Cancer Trial Begins www.timothysykes.com | View source ↗ | www.timothysykes.com | May 5, 2026 | neutral | 0 | 0.6 |
| CLRB Stock Pops As New Cancer Trial Sparks Trading Interest - StocksToTrade | CLRB Stock Pops As New Cancer Trial Sparks Trading Interest StocksToTrade | View source ↗ | StocksToTrade | May 5, 2026 | neutral | 0 | 0.6 |
| Cellectar lines up $140M to fund cancer drug study and FDA filing - Stock Titan | Cellectar lines up $140M to fund cancer drug study and FDA filing Stock Titan | View source ↗ | Stock Titan | May 5, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Jan 8, 2024 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.